Ivermectin Can't Cure Cancer

Key Takeaways

• Preprint claims ivermectin‑mebendazole combo cures cancer, lacks clinical data.
• Wellness Company markets unapproved supplements alongside dubious cancer treatments.
• Laboratory studies show cell‑level effects, not proven in patients.
• Misinformation persists despite extensive evidence ivermectin ineffective for COVID‑19.
• Regulators warn against off‑label use without rigorous clinical trials.

Pulse Analysis

Ivermectin rose to prominence during the COVID‑19 pandemic as a cheap antiparasitic that some fringe groups touted as a miracle cure, despite robust trials disproving any benefit. The drug’s safety profile for treating river blindness and other parasitic infections is well‑established, yet its reputation became entangled with conspiracy‑driven narratives. This backdrop created fertile ground for new, unfounded claims—most recently, a preprint suggesting ivermectin paired with mebendazole can eradicate cancer. The study, conducted by the Wellness Company, merely surveys patients who purchased the regimen, offering no randomized control or survival data.

The Wellness Company’s business model blends legitimate supplements with unapproved, experimental therapies, blurring the line between credible health services and quackery. Their promotion of an ivermectin‑mebendazole cocktail leverages early‑stage laboratory findings that show modest cytotoxic effects on cancer cell lines. However, translating in‑vitro activity to clinical efficacy requires rigorous Phase I‑III trials—something the preprint entirely omits. By presenting anecdotal patient reports as evidence, the paper misleads readers into believing a scientifically unsupported cure exists, potentially diverting patients from evidence‑based oncology care.

The broader implication is a reminder that health misinformation can quickly migrate from one disease context to another, especially when a drug has already been politicized. Regulatory agencies have repeatedly warned against off‑label use of ivermectin without proper trials, emphasizing the risk of adverse effects and delayed proper treatment. For clinicians and investors, the episode underscores the importance of scrutinizing source credibility, demanding peer‑reviewed data, and supporting research pipelines that adhere to stringent clinical standards. In an era where viral misinformation spreads faster than science, maintaining rigorous evidence thresholds is essential to protect public health and preserve trust in medical innovation.